"id","label","rationale","instanceType","uuid:ID","description","name"
"StudyDesign_1","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign","8abd331d-e2df-4553-a2a5-1144fce769e3","The main design for the study","Study Design 1"
